← Leaderboards
Cindy Ann Burklow
Naprogenix, Inc
$3,464,233
Attributed
$3,464,233
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.4M · FY2022–24$2.5M$1.9M$1.3M$625K$0
'22
'23
'24
Funding mix
By agency
NIH$3,464,233 · 2
By mechanism
U44$2,497,816 · 1
R44$966,417 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Dose”
- Sabrina Paganoni · Massachusetts General Hospital$26,348,733
- Suma Babu · Massachusetts General Hospital$26,348,733
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Supriya Menezes · The Emmes Company, Llc$18,394,958
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Dawn Fallacara · Battelle Centers/Pub Hlth Res & Evaluatn$13,673,728
Research focus
DoseAlcohol Abuse TherapyAlcohol DependenceNovel TherapeuticsAlcoholsAlcohol Use DisorderPharmaceutical PreparationsRattusDrug KineticsMolecular TargetLaboratoriesLeadNeurotoxicityMedicalFinancial HardshipClinical TrialsFormulationCanis FamiliarisAlcohol ConsumptionChemical SynthesisDependenceFda ApprovedInvestigationComplex
Grant awards (4)
Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence$99,510
U44 · FY2024 · AA · contact PI
Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence$993,323
U44 · FY2023 · AA · contact PI
Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence$1,404,983
U44 · FY2022 · AA · contact PI
Novel modulators of the dopamine transporter for alcohol and nicotine use disorders$966,417
R44 · FY2022 · AA · contact PI